Tsuruha Holdings (3391) Fundamentals 2026 — P/E 18.5x, Revenue Analysis | SniperIQ
Tsuruha Holdings (3391) is a JP-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥115.7B, trading at ¥2376.50 on the JPX. This SniperIQ fundamentals page covers Tsuruha Holdings's valuation (P/E 18.5x, P/B 1.2x), profitability (net margin 2.5%), revenue (¥1.45T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Tsuruha Holdings's market cap?
Tsuruha Holdings (3391) has a market capitalization of approximately ¥115.7B, trading at ¥2376.50 on the JPX. Market cap moves with the live share price.
What is Tsuruha Holdings's P/E ratio?
Tsuruha Holdings's trailing twelve-month P/E ratio is 18.5x, with a price-to-book (P/B) of 1.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Tsuruha Holdings?
Tsuruha Holdings runs a net profit margin of 2.5%, a gross margin of 30.5%, and an operating margin of 4.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Tsuruha Holdings generate?
Tsuruha Holdings reported revenue of ¥1.45T for fiscal year 2025, with net income of ¥42.7B and earnings per share (EPS) of 144.54. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Tsuruha Holdings pay a dividend?
Tsuruha Holdings offers a trailing dividend yield of about 2.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Tsuruha Holdings financially healthy?
Tsuruha Holdings carries a debt-to-equity ratio of 0.03x and a current ratio of 1.29x, with a market beta of 0.16. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Tsuruha Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Tsuruha Holdings (3391) the key facts are: market cap ¥115.7B, P/E 18.5x, revenue ¥1.45T, 52-week range 1889-2993. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Tsuruha Holdings's full fundamentals live
Get Tsuruha Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.